Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021

Q Wu, W Qian, X Sun, S Jiang - Journal of hematology & oncology, 2022 - Springer
Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …

PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance

M Rose, JT Burgess, K O'Byrne, DJ Richard… - Frontiers in cell and …, 2020 - frontiersin.org
The Poly (ADP-ribose) polymerase (PARP) family has many essential functions in cellular
processes, including the regulation of transcription, apoptosis and the DNA damage …

Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the …

UA Matulonis, D Lorusso, A Oaknin… - Journal of clinical …, 2023 - ascopubs.org
PURPOSE Single-agent chemotherapies have limited activity and considerable toxicity in
patients with platinum-resistant epithelial ovarian cancer (PROC). Mirvetuximab …

Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology

DK Armstrong, RD Alvarez, JN Bakkum-Gamez… - Journal of the National …, 2021 - jnccn.org
Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the
United States and is the country's fifth most common cause of cancer mortality in women. A …

PARP inhibitor resistance: the underlying mechanisms and clinical implications

H Li, ZY Liu, N Wu, YC Chen, Q Cheng, J Wang - Molecular cancer, 2020 - Springer
Due to the DNA repair defect, BRCA1/2 deficient tumor cells are more sensitive to PARP
inhibitors (PARPi) through the mechanism of synthetic lethality. At present, several PAPRi …

Advances in ovarian cancer care and unmet treatment needs for patients with platinum resistance: a narrative review

DL Richardson, RN Eskander, DM O'Malley - JAMA oncology, 2023 - jamanetwork.com
Importance Platinum-based chemotherapy has been the standard of care for ovarian cancer
for the past 3 decades. Although most patients respond to platinum-based treatment …

[HTML][HTML] A decade of clinical development of PARP inhibitors in perspective

J Mateo, CJ Lord, V Serra, A Tutt, J Balmaña… - Annals of …, 2019 - Elsevier
Genomic instability is a hallmark of cancer, and often is the result of altered DNA repair
capacities in tumour cells. DNA damage repair defects are common in different cancer types; …

High-grade serous ovarian cancer: basic sciences, clinical and therapeutic standpoints

MA Lisio, L Fu, A Goyeneche, Z Gao… - International journal of …, 2019 - mdpi.com
Among a litany of malignancies affecting the female reproductive tract, that of the ovary is the
most frequently fatal. Moreover, while the steady pace of scientific discovery has fuelled …

State-of-the-art strategies for targeting the DNA damage response in cancer

PG Pilié, C Tang, GB Mills, TA Yap - Nature reviews Clinical oncology, 2019 - nature.com
Genomic instability is a key hallmark of cancer that arises owing to defects in the DNA
damage response (DDR) and/or increased replication stress. These alterations promote the …

Revolutionizing DNA repair research and cancer therapy with CRISPR–Cas screens

SW Awwad, A Serrano-Benitez, JC Thomas… - … Reviews Molecular Cell …, 2023 - nature.com
All organisms possess molecular mechanisms that govern DNA repair and associated DNA
damage response (DDR) processes. Owing to their relevance to human disease, most …